Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Neuromuscular Blockade
Interventions
DRUG

Rocuronium

Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.

DRUG

Sugammadex

Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
collaborator

MSD Korea Ltd.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER

NCT03039543 - Neuromuscular Blockade During Transurethral Resection of Bladder Cancer | Biotech Hunter | Biotech Hunter